Serine hydroxymethyltransferase
Serine hydroxymethyltransferase | |||||||||
---|---|---|---|---|---|---|---|---|---|
ExPASy NiceZyme view | | ||||||||
KEGG | KEGG entry | ||||||||
MetaCyc | metabolic pathway | ||||||||
PRIAM | profile | ||||||||
PDB structures | RCSB PDB PDBe PDBsum | ||||||||
|
Serine hydroxymethyltransferase (SHMT) is a
Structure
The structure of the SHMT monomer is similar across prokaryotes and eukaryotes, but whereas the active enzyme is a dimer in prokaryotes, the enzyme exists as a tetramer in eukaryotic cells, though the evolutionary basis for this difference in structure is unknown.[1] However, the evolutionary path taken by SHMT going from prokaryotic dimeric form to the eukaryotic tetrameric form can be easily seen as a sort of doubling event. In other words, the eukaryotic SHMT tetramer resembles two prokaryotic dimers that have packed together, forming what has been described as a “dimer of dimers.”[3] The interaction between two monomers within a dimer subunit has been found to occur over a greater contact area and is thus much tighter than the interaction between the two dimers.[3] Human serine hydroxymethyltransferase 2 (SHMT2) regulates one-carbon transfer reactions required for amino acid and nucleotide metabolism, and the regulated switch between dimeric and tetrameric forms of SHMT2, which is induced by pyridoxal phosphate,[4] has recently been shown to be involved in regulation of the BRISC deubiquitylase complex, linking metabolism to inflammation. The SHMT2 dimer, but not the PLP-bound tetramer, is a potent inhibitor of the multimeric BRISC complex, revealing a potential mechanism for SHMT2 regulation of inflammation.[5]
A single SHMT monomer can be subdivided into three domains: an
The active site structure is highly conserved across eukaryotic and prokaryotic forms. The PLP is anchored by means of a
Mechanism
The mechanism commonly ascribed to SHMT enzymatic activity is a transamidation followed by a cleavage of amino acid side chain from the backbone.[7] The N-terminal amine of serine makes a nucleophilic attack on the aldimine between the SHMT lysine (Internal Aldimine) and the PLP aldehyde to form a gem-diamine, and then the N-terminal amine lone pair comes down to displace the lysine, forming a new aldimine, this time with the serine (External Aldimine).[7][8] It is believed that a nearby tyrosine is responsible for much of the proton transfers that occur during the transaldimination.[7][9][10]
Once the serine is bonded to PLP, PLP triggers the α-elimination of the hydroxymethyl group of the substrate (serine). This group is released as a formaldehyde molecule because a nearby glutamate abstracts the proton from the hydroxyl group. Afterwards, the nucleophilic amine on THF attacks the free formaldehyde intermediate to make the carbinolamine intermediate.[8][12] In the second case, the nucleophilic amines on THF attack the serine side chain carbon, simultaneously forming a carbinolamine intermediate on the THF and a quinoid intermediate with the PLP.[8][13] However, THF is not an obligate substrate for SHMT, meaning the cleavage of serine and other β-hydroxy amino acids (such as threonine) can occur without the presence of THF and, in this case, the mechanism is a retro-aldol cleavage.[14] Also, it seems that the subsequent dehydration of the carbinolamine intermediate to form the methylene bridge and fully cyclize into 5,10-CH2-THF is not catalyzed by the enzyme and this reaction may occur spontaneously.[8] In fact, this conversion could occur outside the enzyme, but a study shows that this reaction is faster and thermodynamically favourable when occurs inside the SHMT aided by the Glu57 residue. Moreover, the cyclisation of the carbinolamine intermediate to form 5,10-CH2-THF is essential to Glu57 restore its proton that is used to protonate the quinonoid intermediate and complete the catalytic cycle.[12]
Clinical significance
SHMT has also undergone investigation as a potential target for antimalarial drugs. Research indicates that the active site environment of Plasmodium SHMTs (PSHMTs) differs from that of human cytosolic SHMT, allowing for the possibility of selective inhibition of PSHMT and, thus, the treatment of malaria infections.[17] In particular, certain pyrazolopyran molecules have been shown to have a selective nanomolar efficacy against PSHMTs. Poor pharmacokinetics, however, have prevented these pyrazolopyrans from being effective in living models.[18]
Isoforms
Bacteria such as
In mammals, the enzyme is a tetramer of four identical subunits of approximately 50,000 daltons each. The intact holoenzyme has a molecular weight of approximately 200,000 daltons and incorporates four molecules of PLP as a coenzyme.[20]
Other reactions
As well as its primary role in folate metabolism, SHMT also catalyzes other reactions that may be biologically significant, including the conversion of 5,10-Methenyltetrahydrofolate to 10-Formyltetrahydrofolate.[2] When coupled with C1-tetrahydrofolate synthase and tetrahydropteroate, cSHMT also catalyzes the conversion of formate to serine.[2]
Role in Smith–Magenis syndrome
Smith–Magenis syndrome (SMS) is a rare disorder that manifests as a complex set of traits including facial abnormalities, unusual behaviors, and developmental delay.[21] It results from an interstitial deletion within chromosome 17p11.2, including the cSHMT gene and a small study showed SHMT activity in SMS patients was ~50% of normal.[21] Reduced SHMT would result in a reduced glycine pool, which could affect the nervous system by reducing the functioning of NMDA receptors. This could be a potential mechanism for explaining SMS.[21]
Figures
References
- ^ PMID 12686103.
- ^ PMID 2201683.
- ^ PMID 9753690.
- S2CID 11561274.
- PMID 27835992.
- PMID 10656824.
- ^ PMID 21059411.
- ^ PMID 16125438.
- PMID 21854048.
- PMID 26610130.
- PMID 11877399.
- ^ S2CID 105838672.
- PMID 15170323.
- PMID 22141341.
- ^ PMID 21371789.
- PMID 25677305.
- PMID 24698160.
- PMID 25785478.
- ^ Besson V, Nauburger M, Rebeille F, Douce R (1995). "Evidence for three serine hydroxymethyltransferases in green leaf cells. Purification and characterization of the mitochondrial and chloroplastic isoforms". Plant Physiol. Biochem. 33 (6): 665–673.
- PMID 5028104.
- ^ PMID 8533763.
- PMID 30787298.
Further reading
- Akhtar M, el-Obeid HA (March 1972). "Inactivation of serine transhydroxymethylase and threonine aldolase activities". Biochimica et Biophysica Acta (BBA) - Enzymology. 258 (3): 791–799. PMID 5017703.
- Blakley RL (December 1960). "A spectrophotometric study of the reaction catalysed by serine transhydroxymethylase". The Biochemical Journal. 77 (3): 459–465. PMID 16748851.
- Fujioka M (1969). "Purification and properties of serine hydroxymethylase from soluble and mitochondrial fractions of rabbit liver". Biochimica et Biophysica Acta (BBA) - Enzymology. 185 (2): 338–349. PMID 5808700.
- Kumagai H, Nagate T, Yoshida H, Yamada H (March 1972). "Threonine aldolase from Candida humicola. II. Purification, crystallization and properties". Biochimica et Biophysica Acta (BBA) - Enzymology. 258 (3): 779–790. PMID 5017702.
- Schirch L, Gross T (November 1968). "Serine transhydroxymethylase. Identification as the threonine and allothreonine aldolases". The Journal of Biological Chemistry. 243 (21): 5651–5655. PMID 5699057.
- Schirch L, Quashnock J (June 1981). "Evidence that tetrahydrofolate does not bind to serine hydroxymethyltransferase with positive homotropic cooperativity". The Journal of Biological Chemistry. 256 (12): 6245–6249. PMID 6787050.
- Quashnock JM, Chlebowski JF, Martinez-Carrion M, Schirch L (January 1983). "Serine hydroxymethyltransferase. 31P nuclear magnetic resonance study of the enzyme-bound pyridoxal 5'-phosphate". The Journal of Biological Chemistry. 258 (1): 503–507. PMID 6848517.
External links
- Serine+Hydroxymethyltransferase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)